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Harvard Medical School, Boston, MassachusettsABSTRACT The therapeutic efficacy of cytokines is often hampered by severe side effects due to their undesired binding
to healthy cells. One strategy for overcoming this obstacle is to tether cytokines to antibodies or antibody fragments for targeted
cell delivery. However, how to modulate the geometric configuration and relative binding affinity of the two domains for optimal
activity remains an outstanding question. As a result, many antibody-cytokine complexes do not achieve the desired level of
cell-targeted binding and activity. Here, we address these design issues by developing a computational model to simulate
the dynamics and binding kinetics of natural and engineered fusion proteins such as antibody-cytokine complexes. To verify
the model, we developed a modular system in which an antibody fragment and a cytokine are conjugated via a DNA linker
that allows for programmable linker geometry and protein spatial configuration. By assembling and testing several anti-CD20
antibody fragment-interferon a complexes, we showed that varying the linker length and cytokine binding affinity controlled
the magnitude of cell-targeted signaling activation in a manner that agreed with the model predictions, which were expressed
as dose-signaling response curves. The simulation results also revealed that there is a range of cytokine binding affinities
that would achieve optimal therapeutic efficacy. This rapid prototyping platform will facilitate the rational design of antibody-cyto-
kine complexes for improved therapeutic outcomes.INTRODUCTIONClinical applications of protein drugs are often limited due
to the tendency of such drugs to act on healthy, nontarget
cells. These undesired interactions lead to toxicities and
reduce the therapeutic index, the ratio between the mini-
mum dose that causes toxicity and the minimum dose that
is therapeutically effective. This is particularly a problem
for cytokine therapeutics. Cytokines are key signaling pro-
teins that bind to cell-surface receptors and activate a set
of well-defined cell signaling networks. Several cytokines,
such as interferon (IFN) and interleukin-2, have already
been clinically approved and many more are under develop-
ment (1). However, systemic administration of cytokines
often leads to severe side effects due to their pleiotropic
actions (2–7), which limits their effectiveness.
Side effects are particularly noteworthy for INFa, which
was one of the first biotechnology products and is currently
used to treat hepatitis B, hepatitis C, and metastatic mela-
noma. Commercial forms include INFa-2a (Roferon) and
INFa-2b (Intron A), which correspond to natural human
IFNs, and PEG INFa-2a (Pegasys) and INFa-2b (PEG-
Intron), which are PEGylated derivatives with a much
longer serum half-life due to their increased Stokes radius
and decreased filtration through the kidney into the urineSubmitted June 26, 2014, and accepted for publication October 3, 2014.
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0006-3495/14/11/2456/11 $2.00(8). INFa is produced directly in response to viral infection
and initiates a Th1 immune response, which is also effective
for killing cancer cells. However, it also induces flu-like
symptoms, which are extremely burdensome for hepatitis
patients, who typically receive a 1-year course of treatment,
and may lead to discontinuation (8). In addition, INFamight
be useful at higher doses for many cancers, but the side
effects have likely prevented the development of such ther-
apies (9). PEGylation of INFa allows for less frequent
dosing, but does not appear to lessen the side effects.
Clinical studies have suggested that the side effects are
dose dependent and result from effects on numerous organ
systems (7), so increasing the target-cell specificity could
bring substantial patient benefit.
Thus far, targeted delivery by genetic fusion of cytokines
to antibodies or antibody fragments via polypeptide linkers
has shown limited success in addressing this issue (recently
reviewed in Kontermann (1)). One reason for this failure
is that the fused cytokine can still act on nontarget cells.
Another possibility is that the geometry of an antibody-cyto-
kine fusion does not allow effective cytokine-receptor bind-
ing. If the bound configuration results in steric hindrance or
a majority of time spent in nonproductive conformations,
the effectiveness of targeting is limited. At this time, a reli-
able technique for designing antibody-fusion proteins to
maximize specific, targeted binding does not exist.
It was previously demonstrated that cell-targeting speci-
ficity could be improved by modulating the relative bindinghttp://dx.doi.org/10.1016/j.bpj.2014.10.007
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cytokine to weaken its binding affinity reduces its activity
on all cell types, whereas fusing it to an antibody rescues
its activity only on cell types that express the antibody’s
target by increasing its effective local concentration. For
targeting to be effective, the antibody’s affinity should be
substantially higher than the cytokine’s. Based on this prin-
ciple, a new class of antibody-cytokine fusions called
chimeric activators, which exhibit a 10- to 20-fold increase
in signal activation on the target cells, was developed. How-
ever, it is not clear how to rationally design the appropriate
cytokine-binding affinity for a given antibody-cytokine pair.
Also, estimates based on the relative binding affinity alone
were not sufficient to quantitatively predict the actual target-
ing effect (10,11).
The activity of an antibody-cytokine chimera is also regu-
lated by its geometric configuration. The domains must be
arranged in a spatial configuration that allows the appro-
priate protein-protein interactions. The geometric configura-
tion of an antibody-cytokine fusion can be modulated by
modifying the linker between the two protein domains.
The length and flexibility of the linker have a significant
impact on the accessibility of the antibody and cytokine to
their respective binding targets. For example, a sufficient
separation between the two protein domains is necessary
for optimal fusion protein activity (12–19). Moreover, rigid
linkers often result in better protein domain separation
and fusion protein activity compared with flexible linkers
(12–19). However, it is not clear how the geometric config-
uration for optimal antibody-cytokine fusion activity can be
quantitatively modulated in a given context.
The development ofmulticomponent targeted protein ther-
apeutics has been hampered by a lack of understanding of the
interplay between the spatial and kinetic rate elements within
such proteins, even though these are engineerable. Our
broader goal in this work was to develop a theory that charac-
terizes the contributions of these spatial and kinetic rate ele-
ments well enough to define a function TI(L, m, e) that can
reliably predict the behavior of a given construct in a given
experimental or therapeutic context, whereTI is the therapeu-
tic index, L is the spatial properties of the system,m is the ki-
netic rate parameter information, and e is the experimental
context.We define the term ‘‘targeting effect’’ to mean the ra-
tio of EC50 values (half-maximal effective concentrations)
between nontarget and target cells. The linker effect is the
ratio of EC50 values between constructs with different linker
lengths. The mutation effect is the ratio of targeting effects
between constructs with different mutations applied to the
cytokine that affect its binding kinetics. The linker effect
and mutation effect correspond to the two types of variables
that we can control, namely, spatial and kinetic variables.
We developed a unified computational and experimental
approach to quantitatively evaluate how the combination
of a given linker geometry and reduction in cytokine binding
affinity affects the activity of an antibody-cytokine complex.To demonstrate the utility of our system, we investigated the
effects of linker length and IFNa binding affinity on the ac-
tivity of IFNa complexes that target a B cell antigen, CD20.
This was motivated by recent work in which an anti-CD20
antibody-IFNa fusion protein eradicated B cell lymphoma
tumors with reduced IFNa toxicity in mouse models (20),
and previous chimeric-activator work that showed success
in targeting IFNa to cells expressing epidermal growth fac-
tor receptor (10) and targeting erythropoietin to red blood
cell precursors (11).
We apply a two-component computational modeling
approach that is composed of a constrained Brownian dy-
namics (CBD) simulation method and an ordinary differen-
tial equation (ODE) model (Fig. 1 C). The CBD simulation
uses a coarse-grained 3D model of an antibody-cytokine
complex (Fig. 1,A andB) to determine how a given linker ge-
ometry will affect the cytokine binding dynamics. The CBD
simulation results, along with other IFNa-receptor binding
parameters, are used as inputs for the ODEmodel to generate
the simulated pharmacodynamics of the antibody-cytokine
complexes. The ODE model tracks the kinetic transitions
among all possible protein binding states on the cell surface
(Fig. 1 F) and generates quantitative predictions that can be
compared directlywith experimental invitro Stat1 phosphor-
ylation (an immediate downstream measure of binding) for
target and nontarget cells (see Materials and Methods for
details). Based on computational practicality and available
data, we take a full-systemmodeling approach that is charac-
teristic of recent directions in systems biology (21). The
model is based on physical mechanisms rather than arbitrary
functional fits, and as such contains only parameters with
direct physical meaning that are either already determined
or amenable to future experimental verification.
To test the computational model, we developed a
modular, self-assembling platform on which an antibody
fragment and a cytokine are conjugated via a DNA linker
(Figs. 1 A and S1 in the Supporting Material). The pre-
dictable Watson-Crick basepairing and rigidity of double-
stranded DNA (persistence length ~50 nm (22,23)) allow
for programmable linker geometry. Protein-DNA conjuga-
tion was accomplished by SNAP-tagging chemistry (24).
The assembled DNA-protein complexes then function as a
form of antibody-cytokine complex. The activity of these
complexes on cells that express or do not express CD20
(the antibody target) can then be measured and compared
with our model predictions. Our results provide mechanistic
insights that will aid in the design of antibody-cytokine
complexes for improved therapeutic outcomes.MATERIALS AND METHODS
CBD modeling
We extend the CBD simulation system described by Robinson-Mosher et al.
(25) for our antibody-cytokine complexes. (An illustrative simulationBiophysical Journal 107(10) 2456–2466
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FIGURE 1 Two-component simulation model.
(A) All-atom representation of the chimeric acti-
vator complex. The complex consists of an anti-
CD20 scFv-SNAP fusion protein conjugated to an
oligonucleotide that is hybridized to its comple-
mentary strand, which in turn is conjugated to an
IFNa-SNAP fusion protein. (B) Coarse-grained rep-
resentation of the chimeric activator complex. Each
domain of the chimeric activator complex is repre-
sented as a simple geometric object for simulation.
(C) Schematic of the CBD and ODE simula-
tion model. (D) Simplified representation of
complex with its binding partners, CD20, IFNAR1,
and IFNAR2. (E) CBD simulation approach to
computing the effect of the linker on targeted
IFNa binding. We create a 3D representation of
the complex with the anti-CD20 scFv bound to its
antigen on the target (CD20þ) cell surface. The
model then tracks the constrained Brownian mo-
tions of the components of the complex and calcu-
lates the accessibility of IFNa to its receptors. (F)
ODE model for tracking chimeric activator binding
states. The ODE model simulates and tracks the ki-
netic transitions of all possible bound states of an
anti-CD20 scFv-IFNa complex on the cell surface.
When IFNa is bound to both IFNAR1 and IFNAR2,
we refer to this state as complete IFNa binding,
which leads to Stat1 phosphorylation. The separate
entities in the diagram correspond to populations
tracked in the ODE model. To see this figure in
color, go online.
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To represent rigid DNA linkers and better represent the protein domains, we
add the capacity to handle capsule-shaped rigid structures and electrostatic
interactions between the charged DNA and cell membrane. We assume a
uniform charge distribution along the length of the DNA and a uniform
planar charge density on the cell membrane, and account for Debye-Hu¨ckel
charge screening due to the ionic strength of the medium. To handle
nonspherical rigid structures, one must address nonisotropic diffusion coef-
ficients and nonsphere-sphere steric interactions. We use the Perrin friction
factors for a prolate spheroid for the diffusion terms (26). We handle steric
constraints by treating each rigid structure as a capsule, noting that the
surface of a capsule is defined by the set of points equidistant from a line
segment. The distance between two capsules or a capsule and sphere can
therefore be determined in closed form from the formulae for segment-
segment or point-segment distance, which allows a closed-form expression
for the constraint.
CBD simulations for chimeric activators were initialized with the anti-
CD20 antibody single-chain variable fragment (scFv) constrained to remain
bound to CD20 in the cell membrane (Fig. 1 E) to compare the effects of
different linker types on IFN binding in the target-bound configuration.
The scFv is connected to a SNAP domain by a short flexible linker, thence
to the DNA linker (15, 30, or 45 bp in length), thence to a second SNAP
domain, and thence to the IFN domain. SNAP is a modified human O6-
alkylguanine-DNA alkyltransferase that specifically and covalently binds
to benzylguanine (BG)-labeled substrates (24).
The domains are connected by 9 A˚ flexible linkers fixed to precise points
on the domain surface, except for the connection between SNAP and the
anti-CD20 scFv, which is a 21 A˚ flexible linker. The CD20 molecule is
centered in the x-z plane at the bottom of the simulation domain, with di-
mensions of 140 140 140 nm3 to avoid edge effects, which corresponds
roughly to the density of CD20 on K562 cells (although the density does notBiophysical Journal 107(10) 2456–2466affect the simulation model). The simulation parameters of the medium
correspond approximately to human blood, with a temperature of 37C,
dynamic viscosity of 3.5 cP (27), dielectric constant of 74.5 (28), and ionic
strength of 300 mol/m3 (29). The charge of the DNA linker is 2e per
basepair and the charge density of the membrane is .2 e/A˚2, a parameter
that was estimated based on fitting the model to the data. Each simulation
is run for 1 ms, the first 10 ms of which are discarded to allow the system
to randomize. The measured quality of binding in arbitrary binding units
(ABU) corresponds to the amount of time the IFN molecule spends near
a productive binding configuration with respect to the distance from the
cell membrane of the binding site on IFN receptors (25).
To turn the ABU into a usable quantity in the ODE model, we must
be able to use it to calculate a rate parameter. The binding activity of a
molecule of IFNa tethered near the cell membrane via linkage to bound
anti-CD20 scFv is equivalent to the binding activity of a freely diffusing
IFNa molecule that is constrained to stay within a certain height above
the membrane. (Due to the geometry and electrostatics of the system, this
height may not be simply interpretable as a linker length.) Therefore, we
conducted simulations with freely diffusing IFN monomer confined to a
range of heights between 10 and 240 nm above the membrane and measured
the same ABU quantities, which allowed us to fit a power law relationship
converting ABU to an equivalent height above the membrane h ¼ (8941.7/
ABU).822. We then used this value as a parameter in the ODE model
to compute rates by assuming that the height can be used to compute an
effective on-rate (see below).ODE model to predict Stat1 phosphorylation
Our ODE model uses experimental conditions, affinity values from the
literature and experiment, and CBD simulation results to predict Stat1
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model is implemented via in-house-written MATLAB scripts (described
in Table S2) using standard built-in functions. The model tracks the concen-
tration of free binder (which may be either antibody-cytokine complex or
IFNa alone), unbound IFNAR1, IFNAR2, and CD20, and the population
of binder bound to any subset of IFNAR1, IFNAR2, and CD20. The model
is expressed in terms of transition rates between binding states based on the
current concentrations in each state (Fig. 1 F), along with rates of endocy-
tosis. Rate parameters are determined either from the literature or, in the
case of the binding affinities between the IFN domains of our fusion con-
structs and their receptors, according to a fit to the experimental results
observed on K562 wild-type (WT; nontarget) cells.
Similarly to the work of Dolda´n-Martelli et al. (30), we use the model
previously described by Lauffenburger and Linderman (31) for the binding
of twomolecules associated with a cell membrane to model the dynamics of
IFNa or anti-CD20 scFv binding to IFNAR1, IFNAR2, or CD20, given that
the complex is already bound to one of the three. The two membrane con-
stituents must be close enough to one another for simultaneous binding to
be geometrically possible, given the linker properties; the rate at which this
occurs is referred to as kþ (see Lauffenburger and Linderman (31) for
details). Once the membrane constituents are in close proximity to each
other, binding occurs according to the familiar rate constants for association
in solution, modified by the increased local concentration due to tethering.
The 2D reaction-limited association rate is then
k0on ¼ kon
ðhNAÞ
where h is as described above and NA is Avogadro’s number. The overall 2D
on-rate for IFNa binding to IFNAR2 given the initial binding to CD20
is then
kc ¼

1
kþ
þ 1
k0on
1
We express all of our binding states as 3D concentrations, so we must
convert kc to a 3D on-rate,
k3Dc ¼ kcNAV

A
where V is the total fluid volume and A is the total surface area of the cells
that are present.
The experimental conditions are a volume of 100mL, 1.5 105 cells, 1062
molecules of IFNAR1 and 3021 molecules of IFNAR2 per K562 WT cell,
890 molecules of IFNAR1 and 2725 molecules of IFNAR2 per K562
CD20þ cell (measured experimentally using QuantiBrite beads; BDBiosci-
ences, San Jose, CA), 250,000 molecules of CD20 per K562 CD20þ cell
(also measured experimentally using QuantiBrite beads), a surface area
of 584 mm2 per cell (32), and an assay time of 30 min. The output of the
ODE system is the integral over time of the amount of colocalized IFNAR1
and IFNAR2, which is the sum of the binder-IFNAR1-IFNAR2 and binder-
IFNAR1-IFNAR2-CD20 species concentrations. The Stat1 phosphorylation
curve is generated by running themodel for a range of binder concentrations,
typically between 1014 and 106 M with samples every 10.3 M.
Our observable, Stat1 phosphorylation, has a direct functional relation
to the stability of the IFNa-IFNAR1-IFNAR2 ternary complex. However,
Stat1 signaling need not be linearly proportional to ternary complex forma-
tion, so it is necessary to construct a standard curve. We ran the simulation
model using the IFN-SNAP fusion as the binder, with values of the IFNAR1
and IFNAR2 binding kinetics taken from Jaks et al. (33), and used the
resulting binding curve along with the experimentally measured Stat1 phos-
phorylation to construct a standard curve relating binding to the observed
Stat1 phosphorylation (previous work related a similar value to cell prolif-
eration (30)). We used this standard curve to convert the predicted binding
results for our constructs to predicted Stat1 phosphorylation curves for
direct comparison with experiment.Computing predicted targeting effect
We calculate the targeting effect for a DNA-protein complex as the ratio of
the EC50 values computed for K562 and K562 CD20þ cells. We compute
the EC50 values by generating predicted Stat1 phosphorylation curves as
above, finding the minimum and maximum values, and using MATLAB
to locate the concentration at which the curve reaches the mean value.BG-DNA conjugation
Complementary oligonucleotide pairs of 15, 20, 30, 35, 40, and 45 nucleo-
tides that do not form secondary structures and have stable hybridization at
37C were designed using NUPACK (34) (see Table S1 for the oligonucle-
otide sequences). The 50 end of the oligonucleotides was first modified with
a primary amine via a C6 linker (purchased from Integrated DNATechnol-
ogies, Coralville, IA). To couple BG to the amine-modified oligonucleo-
tides, 10 mM of BG-GLA-NHS (item S9151S; New England Biolabs,
Ipswich, MA) in DMSO was incubated with 1 mM of the amine-modified
oligonucleotides in PBS at 30C overnight. Excess BG-GLA-NHS was then
removed using Illustra Microspin G-25 columns (item 27-5325-01; GE
Healthcare, Boston, MA). The concentration of the purified BG-modified
oligonucleotide was measured using NanoDrop (Thermo Scientific,
Tewksbury, MA). The conjugation of BG and DNA was verified by high-
performance liquid chromatography (Fig. S2).Expression and characterization of SNAP-tagged
proteins
Human type I IFNa2a (IFNa; GenBank ID:AET86951.1)WTand theR144A
mutantweregenetically fused via aGly4Ser linker to theN-terminusofSNAP-
tag (N9181S;NEB,NewEnglandBiolabs, Ipswich,MA),whichwas then fol-
lowed by a C-terminal 6His tag (Fig. S1 A, GenBank accession numbers
KM043782 and KM043781). Anti-CD20 scFv (designed based on Wu et al.
(35)) was genetically fused via a Gly4Ser linker to the N-terminus of SNAP-
tag, again followed by a C-terminal 6xHis tag (Figs. 1 A and S1 A; GenBank
accession number KM043780). The SNAP-tagged proteins were expressed in
E. coli and purified using HisPur Cobalt spin columns (item 90092; Thermo
Scientific, Tewksbury, MA). The activity of the SNAP-tagged proteins was
characterized by biochemical, biophysical, and cell-based assays.DNA-protein complex assembly
To assemble the anti-CD20 scFv-DNA-IFNa complexes, 1.33 mM of anti-
CD20 scFv-SNAP and 1.33 mM SNAP-IFNa(R144A) were incubated with
2 mM forward and reverse strands of BG-oligonucleotides, respectively, for
1 h at room temperature (Fig. S1 B). The excess BG-oligonucleotides were
then removed using 30 kDaMWCO spin columns (item UFC503024; Milli-
pore, Billerica, MA). The oligonucleotide-labeled anti-CD20 scFv-SNAP
and SNAP-IFNa(R144A) were then mixed at an equimolar ratio and
incubated at room temperature for another hour. To confirm the assembly,
the DNA-protein complexes were resolved by electrophoresis using 2%
agarose gels in Tris-acetate-EDTA buffer supplemented with 25 mM of
MgCl2 for 25 min on ice. The migration of the DNA or DNA-protein com-
plexes was visualized by ethidium bromide staining (Figs. 2 D and S2).K562 cell culture
K562 WT (item CCL-243; ATCC, Manassas, VA) and the transformed
K562 CD20þ cells were a generous gift from Dr. Yvonne Chen. The
CD20 expression was confirmed by immunostaining (Fig. S3). K562 WT
and CD20þ cells were cultured in RPMI medium (item 22400-105; Life
Technologies, Bedford, MA) supplemented with 10% fetal bovine serum
at 37C with 5% CO2 and maintained by renewing the medium everyBiophysical Journal 107(10) 2456–2466
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FIGURE 2 The SNAP-tagged proteins are
biologically active. (A) Stat1 phosphorylation in
K562 CD20þ cells induced by SNAP-IFN fusion
proteins after 30 min. Both IFNa(WT)-SNAP and
IFNa(R144A mutant)-SNAP induced robust Stat1
phosphorylation in K562 CD20þ cells (the EC50
values were 0.04 nM and 17.13 nM, respectively).
The decrease in IFNa activity due to the R144A
mutation was consistent with previous reports
(4,8). (B) Fluorescent staining of K562 WT and
CD20þ cells with DAPI and anti-CD20 scFv-
SNAP conjugated to Alexa Fluor 546. (C) Stat1
phosphorylation assay control performed in K562
CD20þ cells with the non-IFN components of the
chimeric activator complex. (D) Gel-shift assay to
demonstrate oligonucleotide conjugation to protein
complexes via changes in electrophoretic mobility.
To see this figure in color, go online.
2460 Robinson-Mosher et al.3 days. For experiments involving the DNA-protein complexes, the cell
culture medium was also supplemented with 12.5 mM of MgCl2 during
the course of the experiments.ELISA
K562 WT and CD20þ cells were seeded in V-bottom 96-well plates at
1.5 105/well. After incubation with the stimulating proteins or complexes
for 30 min, the cells were spun down in the plates and lysed with 105 mL of
lysis buffer (item 9803; Cell Signaling Technology, Danvers, MA) per well
by incubation on ice for 20 min. The lysates were then spun down at 4C to
remove the insoluble fraction. To quantify the level of phosphorylated Stat1
in each lysate sample, the PathScan phospho-stat1 (Tyr701) sandwich
ELISA kit (item 7234S; Cell Signaling Technology) was used according
to the manufacturer’s protocol. Briefly, 100 mL of the soluble lysate from
each sample was added to one anti-phospho-Stat1 antibody-coated well.
After an overnight incubation at 4C, the wells were washed with the
ELISAwash buffer included in the kit. The phosphorylated Stat1 detection
antibody was then added to each well followed by 1 h incubation at 37C.
Horseradish peroxidase-linked streptavidin and TMB (3,3’, 5,5’-tetrame-
thylbenzidine) were then used to detect the bound antibody. The level of
Stat1 phosphorylation was then determined by measuring the absorbance
at 450 nm on a plate reader. The effective half-maximum concentrations
(EC50) of Stat1 phosphorylation were determined from the dose-signaling
curves using a four-parameter sigmoidal fit in GraphPad Prism (La
Jolla, CA).RESULTS
Two-component computational model for
antibody-cytokine complex activity
The CBD simulation model first creates a 3D representation
of the antibody-cytokine complex on the target cell surfaceBiophysical Journal 107(10) 2456–2466and then tracks the constrained Brownian motions of the
components of the complex (Fig. 1 E). The simulations
are initialized with the antibody fragment constrained to
remain bound to the target antigen on the cell membrane.
The simulation predicts the increase in effective IFNa
concentration near the cell membrane as a result of CD20
binding (see Materials and Methods for details), which
can then be used to compute the rate parameters. We devel-
oped the CBD simulation method by extending the molecu-
lar-dynamics simulation framework previously developed in
our group (25). We added the capacity to handle nonspher-
ical rigid structures for modeling rigid linkers and protein
domain geometry. We also considered the electrostatic
interactions between the negatively charged DNA and cell
membrane (see Materials and Methods for details).
Our ODE model generates predicted Stat1 phosphoryla-
tion curves that depend on experimental conditions, binding
affinity values, and CBD simulation results that are used to
compute rate parameters. The model tracks the concentra-
tion of molecules in each possible binding state over time.
In the case of the anti-CD20 scFv-IFNa complexes, the
possible binding states are the free anti-CD20 scFv-IFNa
complex; unbound IFNAR1, IFNAR2, and CD20; and the
population of every binding permutation (Fig. 1 F). The
output of the ODE system is the integral over time of
the amount of IFNa-IFNAR1-IFNAR2 ternary complex
(i.e., complete IFNa binding), which is then converted to
the Stat1 phosphorylation level (see Materials and Methods
for details). This generates predicted Stat1 phosphorylation
curves for direct comparison with experiment.
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linkers
We assembled IFNa complexes that target B cells by syn-
thesizing SNAP-IFNa, SNAP-IFNa(R144A), anti-CD20
scFv-SNAP, and BG-modified oligonucleotides (Fig. S1).
SNAP-tagged IFNa and anti-CD20 scFv are conjugated
to BG-labeled oligonucleotides and form a DNA-protein
complex through DNA hybridization (36,37). The R144A
mutation, which weakens IFNa-IFNAR2 binding, was
introduced to achieve increased specificity for target cells
via the chimeric activator effect (i.e., when a fusion protein
is constructed consisting of one domain that binds to a target
epitope and one domain that stimulates cell signaling, the
increase in signaling on cells that express the target epitope
over those that do not is greater if the affinity of the stimu-
lating domain for its receptor is weakened compared with
the WT) (10).
The SNAP-tagged proteins were biologically active.
IFNa-SNAP induced 398.4-fold greater Stat1 phosphoryla-
tion than IFNa(R144A)-SNAP in K562 CD20þ cells
(Fig. 2 A; the EC50 values were 0.04 nM and 17.13 nM,
respectively). The decrease in IFNa activity due to the muta-
tion was roughly consistent with previous reports (4,10). The
anti-CD20 scFv-SNAP was also functional, as demonstrated
by the specific binding of fluorescently labeled scFv to the
K562 CD20þ cell surface (Fig. 2 B). As an experimental
control, we showed that the anti-CD20 scFv-SNAP and the
BG-modifiedDNA linkers did not induce Stat1 phosphoryla-
tion (Fig. 2 C). To verify the formation of the anti-CD20-
DNA-IFNa complexes, we performed a gel-shift assay.
Assembled DNA-protein complexes showed retarded gel
migration compared with the DNA linkers alone (Fig. 2 D).
The sequences of the DNA linkers are shown in Table S1.Predicted and observed effects of linker geometry
and IFNa binding affinity
By performing CBD simulations of the DNA-protein com-
plexes with 15, 30, and 45 bp DNA linkers, we predicted
a monotonic decrease in the IFNa binding enhancementA B C D
region is the intersection between the sampled space and the possible binding
IFNa cannot bind. (C) Expanded diagram of the possible binding region, showing
of the likelihood of binding in a given configuration takes into account both the di
and the angular distance of binding site from its optimal orientation, q. The CB
aggregates the results to compute an overall binding likelihood measure for a give
linker length was calculated via CBD simulation. We ran 40 simulations, eachdue to anti-CD20 binding with increasing linker length
(Fig. 3 D). We expected that longer linkers would exhibit
reduced binding enhancement as a result of the greater
proportion of time spent far away from the membrane
(Fig. 3, A and B) and the greater repulsion due to the
increased negative charge. Although it is also possible for
a linker to exhibit reduced binding enhancement because
it is too short to span the two receptors (25,38), this was
not expected in our system due to the inclusion of the
SNAP domains (Fig. 1 B). The predicted binding enhance-
ment in ABU (Fig. 3 C) for the 15 bp linker complex was
~30 times greater than that of the 45 bp linker, which led
to an ~17-fold difference in predicted k0on (see Materials
and Methods).
Modeling of signal transduction also led to a prediction
that increasing linker length would decrease the cell-
targeted signaling activation by anti-CD20 scFv-DNA-
IFNa(R144A) complexes (see Fig. 3 D and Materials and
Methods). We first simulated the activity of the anti-CD20
scFv-DNA-IFNa(R144A) complexes on target cells and
generated the predicted Stat1 phosphorylation level as a
function of the complex concentration (Fig. 4 A, bottom).
The simulations predicted a 22.5-fold targeting effect for
Stat1 phosphorylation on target versus nontarget cells and
a 11.2-fold linker effect between the 15 bp and 45 bp linker
complexes (Fig. 4 A, bottom).
To test the validity of our model predictions, we measured
the activation of Stat1 phosphorylation, a measure of IFNa
signaling, in cells with and without CD20 expression.
The assembled DNA-protein complexes induced enhanced
IFNa signaling in the target (CD20þ) cells in a manner
that qualitatively agreed with the simulation results
(Fig. 4, A and C). We stimulated K562 WT and K562
CD20þ cells with assembled anti-CD20 scFv-DNA-
IFNa(R144A) complexes. We evaluated the potency of the
DNA-protein complexes by determining the EC50 from
the Stat1 phosphorylation curves. The complex with the
short (15 bp) linker showed a 42.2-fold targeting effect for
Stat1 phosphorylation. The signaling enhancement
decreased as the linker length increased (12.3-fold decrease
in EC50 when the linker length increased from 15 to 45 bp).FIGURE 3 CBD simulation results. The CBD
simulation results allow us to compute the effects
of linker length on the ability of IFN to bind to
its receptors. (A) Exploration of space near the
membrane by IFNa when the anti-CD20 scFv is
bound to CD20. The green ellipse is the full space
sampled by IFNa, the tan region is where it is
possible for IFNa to bind to its receptors, and the
purple region is the cell membrane. The shaded
region. (B) Longer linkers increase the proportion of conformations where
the conditions that affect the calculated likelihood of binding. The measure
stance of the IFNa binding site from the optimal height off the membrane, d,
D simulation computes the likelihood of binding at every step in time and
n construct (in ABU). (D) The likelihood of binding in ABU as a function of
1 ms long, for each linker length. To see this figure in color, go online.
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FIGURE 4 The linker length and IFNa binding
affinity modulate the targeted cell signaling
activation by antibody-cytokine complexes. K562
(nontarget) and K562 CD20þ (target) cells were
incubated with DNA-protein complexes (as shown
in Fig. 1 A, with three different DNA linker lengths)
for 30 min, lysed, and assayed for Stat1 phosphor-
ylation by ELISA. Simulations were performed us-
ing the two-component approach described in Fig. 1
to model the experimental results. (A and B) Stat1
phosphorylation curves are shown for DNA-protein
complexes incorporating (A) IFNa(R144A)-SNAP
and (B) IFNa(WT)-SNAP. (C and D) EC50 values
were calculated and compared for the experimental
and simulated data by fitting a four-parameter logis-
tic function to the curves for the (C) IFNa(R144A)-
SNAP and (D) IFNa(WT)-SNAP complexes. To
see this figure in color, go online.
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Designing Targeted Therapeutic Proteins 2463There was no substantial linker effect in the nontarget cells
(Fig. 4 A, top).
The enhanced signaling due to CD20 targeting was
diminished when WT IFNa was used instead of
IFN(R144A). The simulation results predicted a 17.2-fold
targeting effect for Stat1 phosphorylation and an 8.7-fold
difference in EC50 between the 15 and 45 bp linker com-
plexes (Fig. 4 B, bottom). There was qualitative agreement
with the experimental results (Fig. 4, B andD). The complex
with the 15 bp linker showed a 14.9-fold targeting effect for
Stat1 phosphorylation, and there was a 27.8-fold difference
between the 15 and 45 bp linker complex (Fig. 4B middle).
There was no substantial linker effect in the nontarget cells
(Fig. 4 B, top).Relationship of the targeting effect with IFN
binding affinity
It has been shown that the activity of IFNa is proportional to
the product of the subunit binding affinities (39). We there-
fore consider adjustments to these affinities to be good can-
didates for modifying the activity of our DNA-protein
complexes. It was previously shown that fusions constructed
using weakened mutant versions of IFNa achieve a greater
targeting effect than those obtained using the WT (the
chimeric activator effect (10)), but no model exists at pre-
sent to indicate how strong a mutation will be optimal. We
investigated the effect of mutations in the binding affinity
of IFNa for each of its receptors on the targeting effect.
Our simulations predicted that there is an optimal range
of IFNa receptor subunit binding affinities, rather than a
single optimum, to achieve a maximal targeting effect. As
observed above (Fig. 4), the binding affinity of IFNa plays
a critical role in modulating the cell-targeted signaling acti-
vation. We show a targeting effect landscape corresponding
to a range of kon
IFNAR1 from 104 to 1010 and kon
IFNAR2 from
102 to 1010, with other parameters corresponding to WT
IFNa and the 15 bp linker (Fig. 5). The targeting effectsteady maximum. The approximate locations of IFNa WT and R144A are in
binding affinities to be chosen within the maximal targeting effect region. Todeclines substantially for kon
IFNAR2 values above ~105 and
somewhat for kon
IFNAR1 values above ~108. The ability to
generate this landscape for a given antibody/cytokine sys-
tem will allow one to select the appropriate mutation
strength for optimal targeting.DISCUSSION
The broad goal of this work was to develop a system for
predicting the therapeutic behavior of artificial therapeutic
fusion proteins as a function of genetically engineerable fea-
tures. Such features include the binding geometry, length,
flexibility, and charge of linkers between domains, and
the affinities, on-rates, and off-rates of individual domains
for their targets. A priori, it seems likely that the system
behavior would be a complicated, nondecomposable func-
tion of these variables, and that the resulting design space
for engineered proteins could be quite large. In particular,
human intuition and static modeling may not be sufficient
to guide the design, and current methods for producing anti-
body-cytokine fusions are too laborious to allow a thorough
exploration of the design space.
Protein engineers have attempted to create chimeric
multidomain protein complexes for many years. The design
approach remains largely focused on the qualitative func-
tional combination and use of nonmutant natural protein
domains (40). Ideally, targeted antibody-cytokine fusions
designed for simultaneous binding of both antibody and
cytokine to the same target cell should be driven by the anti-
body element, but the on-rates and affinities of antibodies
and nonmutant cytokines are often similar. This complex
3D dynamic process requires coordination of the spatial
configuration and binding affinity of the protein domains.
We developed a two-component computational model
to quantitatively evaluate the effects of geometric config-
uration and relative binding affinity on antibody-cytokine
fusion activity. We also implemented an experimental
system that allows users to rapidly build and testFIGURE 5 Simulation across a range of recep-
tor binding affinities predicts a region of maximal
targeting effect. We performed ODE simula-
tions for a wide range of physiologically plau-
sible kon
IFNAR1 and kon
IFNAR2 values to predict
Stat1 phosphorylation curves for both K562 WT
and K562 CD20þ cells. We used koffIFNAR1 and
koff
IFNAR2 values corresponding to those of WT
IFNa and linker parameters corresponding to
the 15 bp linker (holding kon constant and instead
plotting against koff results in an essentially
identical landscape). The targeting effect was
computed as the ratio of the Stat1 phosphoryla-
tion EC50 values on the K562 WT cells to those
on the K562 CD20þ cells. The results indicate
that the targeting effect is relatively low for
high on-rate values and quickly increases to a
dicated on the landscape. Optimal chimeric activator designs will require
see this figure in color, go online.
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properties. We applied this combined approach to quantita-
tively evaluate the effects of linker length on anti-CD20
scFv-IFNa chimeric complexes, which potentially can be
used to treat B cell lymphoma (20).
We found that increasing the length of a stiff DNA linker
decreased the magnitude of the cell-targeted signal activa-
tion, as predicted by both modeling and experiment
(Fig. 4). We also found that the targeting effect of our
scFv-DNA-cytokine construct can be expected to reach a
maximal plateau for low values of IFNa binding affinity
for its receptors, which is consistent with observations in
previous chimeric activator studies and offers an approach
for designing chimeric activator constructs in the future
(Fig. 5).
Here, we took a fine-grained approach to mechanistic
numerical modeling of the IFNa signaling system. Previous
studies modeled chimeric cytokine complexes by treating
IFN binding as though it were a single event (30). However,
the dynamics of signaling via colocalization of two IFNa
receptors is substantially different from that of signaling
via a single receptor (31,33,41). By accurately capturing
the details of the cytokine-receptor binding dynamics, we
can better determine the important factors that modulate
the system behavior.
The presence of free parameters in a modeling system
limits the model’s predictive power, especially if they can
be adjusted to fit any possible set of observable data. The
application of our model is limited by imperfect knowledge
of some of the system parameters, which are thus neces-
sarily free parameters; however, the necessity to account
for multiple linker lengths and both the IFNa WT and
R144A mutant complexes reduces the possibility of overfit-
ting. We also constrained the parameter values that had to
be estimated by information from the literature on what is
plausible. The binding affinity for the anti-CD20 scFv is
not known a priori and was estimated as the value that
best fit both the WT and R144A mutant data.
The initial version of the model did not account for elec-
trostatic forces between the cell membrane and the charged
DNA linker. We had to take these forces into account
to explain the dramatic difference in effect between the
different linker lengths. To fit with the data, the correspond-
ing membrane charge density was ~10 times higher than the
previously reported range (31,42). We hypothesize that the
negatively charged sialic acids on protein-linked oligosac-
charides, which are farther away from the membrane, would
suffer less Debye-Hu¨ckel shielding than the phosphates
on phospholipids. Given these assumptions, the model re-
sults showed good agreement with the experimentally
determined values and provided an adequate mechanistic
explanation for the experimental results. It is also note-
worthy that with the addition of about eight sialic acids in
the engineering of erythropoietin into darbepoetin, receptor
binding and activity on cells decreased significantly evenBiophysical Journal 107(10) 2456–2466though the protein-protein interaction surface of erythropoi-
etin was unaffected (43). Taken together, these results
indicate that modulation of the overall charge may be a
practical protein-engineering strategy to modify the activity
of ligands acting on mammalian cells without introducing
mutations that might disrupt protein-protein interactions in
unpredictable ways.
Although we primarily focused on evaluating the effects
of linker length on antibody-cytokine complex activity,
in theory our two-component computational model can
be applied to simulate the binding events of other multido-
main proteins with a complex geometric configuration. With
the increasing popularity of antibody fusions, bispecific
antibodies, and various forms of multimeric antibodies
for development as therapeutics (1,44), our computational
approach will provide valuable quantitative insights into
the design principles of these protein complexes.
Our results provide not only further support for the effec-
tiveness of the chimeric activator approach to targeted ther-
apeutics but also mechanistic insights into how to modulate
the relative binding affinity for optimal therapeutic efficacy.
This quantitative analysis will help investigators determine
the appropriate mutations for the cytokine to achieve the
desired targeted therapeutic effect. Here, we focused on
optimizing the specificity of IFNa signaling for target cells.
To extend the approach to a more direct prediction of ther-
apeutic efficacy, it will be necessary to model the binding
dynamics over a longer period of time and take additional
factors, such as receptor downregulation and trafficking,
into account. In addition, although the same modeling
approach is applicable to receptor antagonists as well as
the agonist we discuss here, the experimental readout would
be quite different.
The biological response to a cytokine is a complicated
function of receptor binding strength and the trafficking
properties of the ligand-receptor complex. This includes
the propensity of the activated receptor to be endocytosed,
to be either recycled or degraded, and for the ligand to
remain with or dissociate from its receptor in the low-pH
environment of the endosome (45). It is thought that if the
ligand remains receptor bound, it will be degraded or re-
cycled along with the receptor, but if it dissociates in the
endosome, a fixed fraction will be recycled. For example,
Sarkar et al. (46) engineered G-CSF to show enhanced
recycling out of cells by introducing histidines that would
become protonated in the endosome, induce G-CSF/G-
CSFR dissociation, and help the mutant G-CSF avoid being
degraded along with the receptor after endocytosis. Binding
at pH 7.4 was essentially unaffected by these mutations. In
our case, trafficking of the engineered ligand may be influ-
enced by the behavior of both of the receptors to which it is
bound. Modifying the ligand to remain endosomally associ-
ated with either the targeting or activity receptor may be an
additional engineering strategy to enhance cell-specific
signaling. Our model provides a good measure of the effect
Designing Targeted Therapeutic Proteins 2465of our engineering on initial binding and signaling. Addi-
tional modeling including endocytic trafficking processes
(47) could help predict the behavior of engineered fusion
proteins in vivo.
To our knowledge, our work is the first to challenge this
type of modeling with experiments on the effects of linker
geometry in target-active element protein complexes. We
believe our unified computational modeling and experi-
mental approach provides a strong basis for elucidating
the general design principles of antibody-cytokine fusions
and, in theory, other multidomain proteins or protein com-
plexes. This will help us to move toward rational design
of engineered proteins with optimal biophysical properties.SUPPORTING MATERIAL
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